Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events

VANCOUVER, Dec. 24, 2019 -- (Healthcare Sales & Marketing Network) - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has received a Complete Response Letter... Biopharmaceuticals, Cardiology, FDA Correvio Pharma, Brinavess, vernakalant, atrial fibrillation
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news